紫杉醇联合卡铂加甲孕酮二线治疗晚期非小细胞肺癌的临床研究

A Clinical Study of Paclitaxel Combined with Carboplatin and Medroxyprogesterone Acetate in Second Line Treatment of Advanced Non-Small Cell Lung Cancer

目的观察紫杉醇(PTX)联合卡铂(CBP)加甲孕酮(MPA)作为耐药调变剂即PCM方案二线治疗晚期非小细胞肺癌(NSCLC)的疗效及甲孕酮对患者饮食、体重及骨髓的影响。方法70例患者被随机分为治疗组35例,应用PCM方案;对照组35例,应用PC方案。结果治疗组和对照组有效率分别为34.9%和31.4%,中位疾病进展时间分别为4.5个月和4.1个月,中位生存期分别为7.1个月和6.8个月,P>0.05,无统计学意义。治疗组80%患者进食增加,67.1%患者体重增加,对照组22.8%患者进食、体重增加,两组对比有显著差异(P<0.05),治疗组和对照组白细胞下降的发生率分别为31.4%和62.9%,两组有显著差异(P<0.05)。结论PCM方案二线治疗晚期NSCLC疗效明显,且使大部分患者饮食、体重增加,骨髓抑制程度减轻,生活质量提高,值得推广。

Objective To observe the efficacy of Paclitaxel （PTX） combined with Carboplatin （CBP） and Medroxyprogesterone acetate （MPA） to reverse multi-drug resistance, or PCM regimen, in second-line treatment of advanced non-small cell lung cancer, and the influence of MPA on diet, weight and marrow of the patients.Methods A total of 70 patients was randomly divided into two groups, study group （ n = 35） with PCM regimen, and control group （ n = 35） with PC regimen. ResuIts For the treatment group and the control group, the recently efficient rates were 34.9% and 31.4% , the median time to progress was 4.5 months and 4.1 months the median survival was 7.1 months and 6.8 months respectively. However, P 〉 0.05, there was no statistical difference between the two groups. In the treatment group 80% of patients were promoted in diet, but 67.1% in weight, in the control group 22.8% of patients were promoted in diet and weight. The rates of leukocyte descent were 31.4% and 62.9% respectively. There was significant statistic difference between the two groups （ P 〈 0.05） .ConcIusion PCM regimen in second-line treatment for the advanced non-small cell lung cancer is an effective regimen, and it can be added to most patients diet and weight, it can relieve myelosuppression and elevate life quality. This method will be highly recommended surely in the future.